Markets · 1 sources covering this

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to con…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to con…
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/2aa6fa2d28ad1e5467c0b85a16182dcfbea4a30c"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers"></iframe>

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

How 1 sources are covering this